Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.
- Citation:
- Oncologist vol 24 (11) 1497-1501
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Pharmas:
- Exelixis, Inc
- Grants:
- U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748
- Corr. Author:
- Authors:
- Daniel J George Colin Hessel Susan Halabi M Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Michael J Morris Toni K Choueiri
- Networks:
- CA136, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Aged, Anilides, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Kidney Neoplasms, Male, Prognosis, Pyridines, Retrospective Studies, Sunitinib, Survival Rate